Lucia Casadei

Dr. Lucia Casadei

1. The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
+1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Lucia CasadeiLucia Casadei
Lucia Casadei
FFFernanda Costas Casal de Faria
Fernanda Costas Casal de Faria
ALAlexandra G Lopez-Aguiar
Alexandra G Lopez-Aguiar
RPRaphael E. E Pollock
Raphael E. E Pollock
VGValerie Grignol
Valerie Grignol
Liposarcoma (LPS) is the most prevalent soft tissue sarcoma histological subtype. When it occurs in the abdomen the overall survival rate is as low as 10% at 10 years and is fraught with high rates of recurrence, particularly for the more aggressive dedifferentiated subtype. Surgery remains the mainstay of treatment. Systemic therapies for the treatment of metastatic or unresectable disease have low response rates. Deep understanding of well-differentiated and de-differentiated LPS (WDLPS and DDLPS, respectively) oncologic drivers is necessary for the development of new efficacious targeted therapies for the management of this disease. This review discusses the current treatments under evaluation for retroperitoneal DDLPS and the potential targetable pathways in DDLPS.

31 August 2022 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
Lucia CasadeiLucia Casadei
Lucia Casadei
PSPatricia Sarchet
Patricia Sarchet
FFFernanda Costas C. de Faria
Fernanda Costas C. de Faria
FCFederica Calore
Federica Calore
Giovanni NigitaGiovanni Nigita
Giovanni Nigita
RPRaphael E. Pollock
Raphael E. Pollock
EVs have emerged as an important component in tumour initiation, progression and metastasis. Although notable progresses have been made, the detection of EV cargoes remain significantly challenging for researchers to practically use; faster and more convenient methods are required to validate the EV cargoes, especially as biomarkers. Here we show, the possibility of examining embedded EVs as substrates to be used for detecting DNA amplification through ultrasensitive in situ hybridization (ISH). This methodology allows the visualization of DNA targets in a more direct manner, without time consuming optimization steps or particular expertise. Additionally, formalin‐fixed paraffin‐embedded (FFPE) blocks of EVs allows long‐term preservation of samples, permitting future studies. We report here: (i) the successful isolation of EVs from liposarcoma tissues; (ii) the EV embedding in FFPE blocks (iii) the successful selective, specific ultrasensitive ISH examination of EVs derived from tissues, cell line, and sera; (iv) and the detection of MDM2 DNA amplification in EVs from liposarcoma tissues, cell lines and sera. Ultrasensitive ISH on EVs would enable cargo study while the application of ISH to serum EVs, could represent a possible novel methodology for diagnostic confirmation. Modification of probes may enable researchers to detect targets and specific DNA alterations directly in tumour EVs, thereby facilitating detection, diagnosis, and improved understanding of tumour biology relevant to many cancer types.

1 September 2020 in Cancer Letters
Verified
Journal Article
Closed access
Lucia CasadeiLucia Casadei
Lucia Casadei
RPRaphael E. Pollock
Raphael E. Pollock

7 February 2020
Verified
Book Chapter
Closed access
PDF file
AZAbbie Zewdu
Abbie Zewdu
Lucia CasadeiLucia Casadei
Lucia Casadei
RPRaphael E. E Pollock
Raphael E. E Pollock
DBDanielle Braggio
Danielle Braggio

1 February 2020 in Oncoscience
Verified
Journal Article
Open access
Lucia CasadeiLucia Casadei
Lucia Casadei
RPRaphael E. E Pollock
Raphael E. E Pollock
Dedifferentiated liposarcoma (DDLPS) is molecularly characterized by wt p53 and MDM2 gene amplification causing MDM2 protein over-production, the key oncogenic process in DDLPS. Commonly located in fat-bearing retroperitoneal areas, almost 60% of DDLPS patients undergo multifocal recurrence, typically amenable to palliative treatment only, and occasionally develop distant metastasis. These factors lead to an abysmal 10% 10 year overall survival rate. Tumor cell-derived extracellular vesicles (EVs) can facilitate loco-regional malignancy dissemination by depositing molecular factors that participate in the development of pre-metastatic niches for tumor cell implantation and growth. High number of MDM2 DNA molecules was identified within EVs from DDLPS patient serum (ROC vs normal; 0.95) as well as from DDLPS cell lines. This MDM2 DNA could be transferred to preadipocytes (P-a), a major and ubiquitous cellular component of the DDLPS tumor microenvironment (TME), with subsequent P-a production of matrix metalloproteinase 2 (MMP2), a critical component in the metastatic cascade. From here the hypothesis that the DDLPS microenvironment (specifically P-a cells) may participate in DDLPS recurrence events. Since multifocal loco-regional DDLPS spreading is the main cause of the remarkably high lethality of this disease, a better understanding of the underlying oncogenic processes and their regulatory mechanisms is essential to improve the outcome of this devastating disease.

26 March 2022 in Life
Verified
Journal Article
Open access
PDF file
AAAnita Adib
Anita Adib
RSRuhi Sahu
Ruhi Sahu
SMShivangi Mohta
Shivangi Mohta
RPRaphael E. E Pollock
Raphael E. E Pollock
Lucia CasadeiLucia Casadei
Lucia Casadei
Soft tissue sarcomas (STS) are rare malignancies with limited responses to anticancer therapy. Extracellular vesicles (EVs) are a heterogeneous group of bi-lipid layer sacs secreted by cells into extracellular space. Investigations of tumor-derived EVs have revealed their functional capabilities, including cell-to-cell communication and their impact on tumorigenesis, progression, and metastasis; however information on the roles of EVs in sarcoma is currently limited. In this review we investigate the role of various EV cargos in sarcoma and the mechanisms by which those cargos can affect the recipient cell phenotype and the aggressivity of the tumor itself. The study of EVs in sarcoma may help establish novel therapeutic approaches that target specific sarcoma subtypes or biologies, thereby improving sarcoma therapeutics in the future.